Clinical Report: Low-Dose Rivaroxaban Did Not Reduce LV Thrombus After Anterior STEMI

Overview

The APERITIF trial found that low-dose rivaroxaban did not significantly reduce left ventricular thrombus rates in patients with anterior STEMI compared to dual antiplatelet therapy alone, and the primary endpoint was not met.

Background

Left ventricular thrombus formation is a potential complication following anterior ST-segment elevation myocardial infarction (STEMI), which can lead to serious outcomes such as stroke. The addition of anticoagulants like rivaroxaban to dual antiplatelet therapy has been considered to mitigate this risk. Understanding the efficacy of such interventions is crucial for optimizing post-MI management strategies.

Data Highlights

Key Findings

• 14% of patients receiving dual antiplatelet therapy plus rivaroxaban developed LV thrombus.
• 17% of patients receiving dual antiplatelet therapy alone developed LV thrombus.
• No statistically significant difference in thrombus rates between the two groups (P=0.34).
• Minor bleeding occurred in 18% of patients on rivaroxaban compared to 9% on dual antiplatelet therapy alone (P<0.05).
• Major adverse cardiovascular events were rare and similar across both treatment groups (P<0.05).
• Subgroup analyses showed consistent findings across various patient characteristics.

Clinical Implications

The findings suggest that low-dose rivaroxaban does not provide additional benefit in preventing LV thrombus in patients with anterior STEMI when used alongside dual antiplatelet therapy. Clinicians should consider these results, along with the trial's limitations, when making decisions about anticoagulation strategies in this patient population.

Conclusion

The APERITIF trial indicates that the routine addition of low-dose rivaroxaban to dual antiplatelet therapy for LV thrombus prevention after anterior STEMI is not supported by the evidence. Further research may be needed to explore alternative strategies.

Related Resources & Content

1. JAMA Cardiology, 2026 -- Low-Dose Rivaroxaban to Prevent Left Ventricular Thrombosis After Anterior Myocardial Infarction: The APERITIF Randomized Clinical Trial
2. American Heart Association, 2025 -- 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes
3. American College of Cardiology -- RIVAWAR: Rivaroxaban As Effective as Warfarin For Post MI LV Thrombus
4. conexiant — Low-Dose Apixaban Cuts Superficial Thrombosis Risk
5. The ASCO Post — Oral Rivaroxaban Is Noninferior to Standard Anticoagulant Therapy in Acute Pulmonary Embolism
6. Basic Research in Cardiology — Rivaroxaban influences the maturation of neutrophils within the bone marrow environment
7. Clinical Research in Cardiology — Evaluating the Safety of Dobutamine versus Adenosine in Cardiac Magnetic Resonance Imaging for Patients with Left Ventricular Thrombus
8. Low-Dose Apixaban Cuts Superficial Thrombosis Risk
9. Oral Rivaroxaban Is Noninferior to Standard Anticoagulant Therapy in Acute Pulmonary Embolism
10. Rivaroxaban influences the maturation of neutrophils within the bone marrow environment
11. 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes - Professional Heart Daily | American Heart Association
12. Low-Dose Rivaroxaban to Prevent Left Ventricular Thrombosis After Anterior Myocardial Infarction: The APERITIF Randomized Clinical Trial | Anticoagulation | JAMA Cardiology | JAMA Network
13. RIVAWAR: Rivaroxaban As Effective as Warfarin For Post MI LV Thrombus - American College of Cardiology